Polyrizon Ltd. (PLRZ) Stock Price, Quote & News

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is he...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 374 0120

Website: www.polyrizon-biotech.com

Address:

5 HaPnina Street, Ra'anana, Israel

ExploringTrades Aug. 3 at 10:50 PM

Have you seen the Ebola outbreak news this weekend?? 🤯 Make sure to put VRAX onto your watchlist 💎 Ticker VRAX is one of the tiniest float bio-techs that great cash position and Peptides against Ebola! I accumulated a huge amount of shares because of the recent Ebola outbreak. Numbers are rising concerningly fast. The right PR and it could see a big squeeze like the last time we saw an outbreak! $PLRZ )(

0 · Reply

Schizoo Aug. 3 at 5:23 PM

$PLRZ low float. Low volue. Big spread. High short. More buyers than sellers.. hold.

0 · Reply

Schizoo Aug. 3 at 4:19 PM

$PLRZ hold

1 · Reply

Schizoo Aug. 3 at 2:31 PM

$PLRZ swing this 🤌

0 · Reply

Tbirdyguy Aug. 2 at 6:03 PM

$PLRZ 7 weeks since central IRB approval. I would expect news soon on site activation or site level approvals or something we will see ....

0 · Reply

Schizoo Jul. 31 at 1:48 PM

$PLRZ BALLS N PATIENCE PEOPLE

1 · Reply

patrick1956 Jul. 30 at 4:01 PM

$PLRZ ....very bullish

0 · Reply

Schizoo Jul. 30 at 1:07 PM

$PLRZ 🤌

0 · Reply

Schizoo Jul. 29 at 5:23 PM

$PLRZ 🤌

0 · Reply

Schizoo Jul. 29 at 2:56 PM

$PLRZ in for a swing

0 · Reply

Polyrizon announces results from Nasarix biocompatibility evaluation program

Jul 2, 2026, 7:32 AM EDT - 4 weeks ago

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

2026-06-29T13:15:15.000Z - 5 weeks ago

Polyrizon receives central IRB approval for Nasarix

Jun 29, 2026, 8:44 AM EDT - 5 weeks ago

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

2026-06-17T13:22:01.000Z - 6 weeks ago

Polyrizon gets patent for Trap & Target mucoadhesive polymer technology platform

Jun 17, 2026, 8:15 AM EDT - 6 weeks ago

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Jun 15, 2026, 8:05 AM EDT - 7 weeks ago

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

2026-06-10T11:50:59.000Z - 7 weeks ago

Polyrizon receives notice of European patent publication

Jun 10, 2026, 7:47 AM EDT - 7 weeks ago

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

2026-06-08T13:37:19.000Z - 2 months ago

Polyrizon signs agreements with two additional clinical sites for Nasarix study

Jun 8, 2026, 9:25 AM EDT - 2 months ago

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

2026-05-13T13:54:28.000Z - 2 months ago

Polyrizon signs clinical trial agreement with clinical research site for Nasarix

May 13, 2026, 9:25 AM EDT - 2 months ago

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

May 11, 2026, 7:25 AM EDT - 3 months ago

Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

2026-05-04T13:47:12.000Z - 3 months ago

Polyrizon amends patent application claims for intranasal drug delivery platform

May 4, 2026, 8:45 AM EDT - 3 months ago

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

2026-04-28T14:31:03.000Z - 3 months ago

Polyrizon Ltd trading halted, volatility trading pause

2026-04-28T14:25:09.000Z - 3 months ago

Polyrizon Ltd trading resumes

2026-04-27T13:57:32.000Z - 3 months ago

Polyrizon files European patent application for Trap & Target platform

Apr 27, 2026, 9:28 AM EDT - 3 months ago

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

2026-04-23T23:30:28.000Z - 3 months ago

Polyrizon files to sell 0.5M shares of common stock for holders

Apr 8, 2026, 4:16 PM EDT - 4 months ago

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Mar 26, 2026, 9:23 AM EDT - 4 months ago

Polyrizon Provides 2025 and Recent Highlights

Mar 25, 2026, 5:25 PM EDT - 4 months ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

2026-03-24T13:05:32.000Z - 4 months ago

Polyrizon to acquire 20% stake in Colugo for up to $6M

Mar 24, 2026, 8:47 AM EDT - 4 months ago

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

2026-03-17T15:51:34.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

2026-03-17T12:35:48.000Z - 4 months ago

Polyrizon signs agreement with research organization for clinical development

Mar 17, 2026, 8:25 AM EDT - 4 months ago

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

2026-03-10T12:09:52.000Z - 5 months ago

Polyrizon announces production of GMP batch of Clinical Trial Material

Mar 10, 2026, 7:55 AM EDT - 5 months ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

2026-02-26T13:40:23.000Z - 5 months ago

Polyrizon announces results from study evaluating profile of naloxone formula

Feb 26, 2026, 8:12 AM EST - 5 months ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Feb 17, 2026, 11:32 AM EST - 5 months ago

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

2026-02-10T12:10:14.000Z - 6 months ago

Polyrizon intends to acquire a 51% stake in Arrow Aviation

Feb 10, 2026, 6:55 AM EST - 6 months ago

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

2026-02-06T13:01:07.000Z - 6 months ago

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

CMND

Feb 6, 2026, 7:55 AM EST - 6 months ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Feb 4, 2026, 7:12 AM EST - 6 months ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Jan 22, 2026, 9:25 AM EST - 6 months ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Jan 13, 2026, 8:39 AM EST - 7 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 8, 2026, 8:45 AM EST - 7 months ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 5, 2026, 9:07 AM EST - 7 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 2, 2026, 8:30 AM EST - 7 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Dec 29, 2025, 7:20 AM EST - 7 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 19, 2025, 8:20 AM EST - 8 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 11, 2025, 8:15 AM EST - 8 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 8, 2025, 8:55 AM EST - 8 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 4, 2025, 7:32 AM EST - 8 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 3, 2025, 9:28 AM EST - 8 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 2, 2025, 7:55 AM EST - 8 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Nov 6, 2025, 8:55 AM EST - 9 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Oct 6, 2025, 8:21 AM EDT - 10 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Sep 19, 2025, 8:15 AM EDT - 11 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 12, 2025, 7:26 AM EDT - 11 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Aug 14, 2025, 8:14 AM EDT - 1 year ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Jul 15, 2025, 7:55 AM EDT - 1 year ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jun 12, 2025, 7:32 AM EDT - 1 year ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

May 23, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 21, 2025, 7:10 AM EDT - 1 year ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 13, 2025, 7:45 AM EDT - 1 year ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Apr 25, 2025, 7:37 AM EDT - 1 year ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 11, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 1, 2025, 4:09 PM EDT - 1 year ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 1 year ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 27, 2025, 8:25 AM EDT - 1 year ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 25, 2025, 4:04 PM EDT - 1 year ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

ExploringTrades Aug. 3 at 10:50 PM

0 · Reply

Schizoo Aug. 3 at 5:23 PM

$PLRZ low float. Low volue. Big spread. High short. More buyers than sellers.. hold.

0 · Reply

Schizoo Aug. 3 at 4:19 PM

$PLRZ hold

1 · Reply

Schizoo Aug. 3 at 2:31 PM

$PLRZ swing this 🤌

0 · Reply

Tbirdyguy Aug. 2 at 6:03 PM

$PLRZ 7 weeks since central IRB approval. I would expect news soon on site activation or site level approvals or something we will see ....

0 · Reply

Schizoo Jul. 31 at 1:48 PM

$PLRZ BALLS N PATIENCE PEOPLE

1 · Reply

patrick1956 Jul. 30 at 4:01 PM

$PLRZ ....very bullish

0 · Reply

Schizoo Jul. 30 at 1:07 PM

$PLRZ 🤌

0 · Reply

Schizoo Jul. 29 at 5:23 PM

$PLRZ 🤌

0 · Reply

Schizoo Jul. 29 at 2:56 PM

$PLRZ in for a swing

0 · Reply

PandaTrade_ Jul. 28 at 7:51 PM

Seems like Volume is going in to APUS fast now! 🚀 APUS is breaking out with only 450k shares remaining! Great NEWS released, People are just finding it. Don't be late to APUS, It's going parabolic. $BLMZ $PLRZ $BTOG Cretpro

0 · Reply

Tbirdyguy Jul. 28 at 6:00 PM

$PLRZ bad news? Problems with starting trials? Anyone k ow what to is happening??

2 · Reply

patrick1956 Jul. 27 at 2:09 PM

$PLRZ ...some1 is selling shares with the hope of getting cheap shares...if you are lucky grab these shares and wait..just a matter of time we see $25...with positive news on the horizon..imo

1 · Reply

Tbirdyguy Jul. 27 at 1:46 PM

$PLRZ what the fuck do we make of this shit show lol?

0 · Reply

Tbirdyguy Jul. 27 at 11:57 AM

$PLRZ

0 · Reply

BNKK_Sucks_Balls Jul. 26 at 10:26 PM

$PLRZ what are we looking at here...crazy PM action tomorrow?

2 · Reply

NoahMiles11 Jul. 24 at 8:56 PM

$PLRZ

0 · Reply

ExploringTrades Jul. 23 at 10:07 PM

$PLRZ $BTOG Crypto plays

0 · Reply

Note7Creole Jul. 18 at 8:10 PM

$TGHL Shorts are hoping for the RS, their are many exampls of companies canceling a share consolidation tool to meet compliance especially if they see what these two companies did when canceling a RS.. $PLRZ $WHLR But honestly the company can cancel the RS if the ticker closes at or above 1.00 per day. 10 days of compliance stared on the 16th, and we closed at $1.04 on the 17th. We have 8 trading days to go. Wednesday July 29th 2026 is the final day! Stockholders equity remedy will be in compliance once the merger with the 400M valued EnChem America is finalized.. Welcome to a huge pop watch team.. i have 3,191 shares and may add more if we keep above compliance 💪🏾🍻

0 · Reply

Tbirdyguy Jul. 14 at 1:19 PM

$PLRZ looks like market anticipation to me this morning

0 · Reply

topstockalerts Jul. 14 at 1:16 PM

Pre Market Top Gainers PT2 $HAO $LHAI $CLSK $PLRZ $BJDX

1 · Reply

patrick1956 Jul. 13 at 5:01 PM

$PLRZ ...this company is a Zionist control...it hopefully can produce something...remember this was over 1000$...at this level all depends on the propaganda they release...imo

1 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	1,429,814
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A